To some degree, it's actually a lot easier to get genomic results of a population than it is to get really deep clinical data.

Oncology has been very much into precision, right? Whether it's very specific on certain indications and at certain times of kind of tumor progression or whatever it may be. And that precision is now looking to kind of, they're looking in other areas across life sciences for where can we be similar? There are certain areas that are now very highly completed.

From a pharma perspective in terms of treatments, whether that's in cardiovascular or otherwise, cardiovascular's a really good example. And so often someone will go on a drug and then find out, that wasn't the drug that worked for me. They'll come off it, they'll go on to another drug and another drug. And it may not be until they get fourth, maybe fifth line therapy until they finally find a treatment that works for them.

There's a high chance that that treatment could have been identified for a specific phenotype as being particularly effective if they'd had the data when they went through the trial process to understand that.

It's using this clinical data in a very similar way to how you would use genomics to kind of highlight these sub-cohorts for whom these treatments perform and respond particularly well. And that's a key aspect of what we're doing is trying to give people those insights so that people like the pharma companies and the physicians can have faith and understanding in kind of getting those treatments to the right…